Novelty Nobility Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
M&A
- (Cancelled)
- Latest Deal Amount
-
$10.8M
- Investors
-
31
Novelty Nobility General Information
Description
Operator of a biotech company intended to develop antibodies and antibody-drug conjugates to overcome drug resistance. The company focuses on researching novel factors for angiogenesis to develop therapeutic antibodies for treating diseases caused by the growth of aberrant blood vessels, such as retinal diseases and solid cancerous tumors, enabling clients to access new therapeutic options in ophthalmology and oncology for their patients.
Contact Information
Website
www.noveltynobility.comCorporate Office
- Unit 210, 686
- Cheonggyesan-ro
- Seongnam, Gyeonggi 13105
- South Korea
Corporate Office
- Unit 210, 686
- Cheonggyesan-ro
- Seongnam, Gyeonggi 13105
- South Korea
Novelty Nobility Timeline
Novelty Nobility Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 23-Aug-2025 | $10.8M | Cancelled | Clinical Trials - Phase 1 | ||
| 6. Accelerator/Incubator | 07-Apr-2025 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series C) | 11-Nov-2024 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series B) | 15-May-2022 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC | 04-Mar-2021 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 30-Jan-2020 | $8.58M | $9.6M | Completed | Startup | |
| 1. Seed Round | 30-Apr-2019 | $1.05M | $1.05M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Novelty Nobility Patents
Novelty Nobility Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025261271-A1 | Novel anti-cdcp1 humanized antibody and use thereof | Pending | 22-Apr-2024 | ||
| WO-2025226017-A1 | Novel anti-cdcp1 humanized antibody and use thereof | Pending | 22-Apr-2024 | ||
| AU-2025207813-A1 | Bispecific antibody specifically binding to c-kit and vegf, and use thereof | Pending | 12-Jan-2024 | ||
| WO-2025151018-A1 | Bispecific antibody specifically binding to c-kit and vegf, and use thereof | Inactive | 12-Jan-2024 | ||
| WO-2024090927-A1 | Novel anti-cdcp1 antibody and use thereof | Inactive | 24-Oct-2022 | C07K16/2896 |
Novelty Nobility Signals
Novelty Nobility Investors (31)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | |||
| AFW Partners | Venture Capital | Minority | ||
| Brave New Investment | PE/Buyout | Minority | ||
| KDB Capital | PE/Buyout | Minority | ||
| LINE Investment Partners | Venture Capital | Minority |
Novelty Nobility FAQs
-
When was Novelty Nobility founded?
Novelty Nobility was founded in 2017.
-
Where is Novelty Nobility headquartered?
Novelty Nobility is headquartered in Seongnam, South Korea.
-
What is the size of Novelty Nobility?
Novelty Nobility has 21 total employees.
-
What industry is Novelty Nobility in?
Novelty Nobility’s primary industry is Drug Discovery.
-
Is Novelty Nobility a private or public company?
Novelty Nobility is a Private company.
-
What is the current valuation of Novelty Nobility?
The current valuation of Novelty Nobility is .
-
What is Novelty Nobility’s current revenue?
The current revenue for Novelty Nobility is .
-
How much funding has Novelty Nobility raised over time?
Novelty Nobility has raised $60.8M.
-
Who are Novelty Nobility’s investors?
Johnson & Johnson Innovation - JLABS, AFW Partners, Brave New Investment, KDB Capital, and LINE Investment Partners are 5 of 31 investors who have invested in Novelty Nobility.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process